Project Grant HT94252310270
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $931,113 project grant to The University of Texas MD Anderson Cancer Center, with a performance period from November 1, 2024 to October 31, 2027. The grant supports research targeting RNA surveillance machinery in neurofibromatosis type 1 (NF1)-mutant malignant peripheral nerve sheath tumors (MPNSTs). As a leading academic cancer research institution, MD Anderson has extensive expertise...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...
The Defense Health Agency awarded a $819,080 Project Grant to The University of Texas M.D. Anderson Cancer Center to evaluate how maternal dietary exposure affects neurodevelopment and cognition in neurofibromatosis type 1 (NF1) under the Military Medical Research and Development program (CFDA 12.420). The University of Texas M.D. Anderson Cancer Center will conduct research into medical solutions for the battlefield and innovative healthcare for service members and the public by investigating...
The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...
The University of Texas MD Anderson Cancer Center received a $539,453 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop a microfluidics-based approach for isolating antigen-specific T cells in non-small cell lung cancer. The research aims to optimize methods for enriching and identifying T cells that recognize and bind to tumor cells, leveraging this platform to predict clinical outcomes. As a sub-award, the...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
The University of Texas MD Anderson Cancer Center was awarded a $758,337 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through September 2024 to target resistance mechanisms in tumors deficient in the SMARCB1 gene. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through...
The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
The University of Texas M.D. Anderson Cancer Center has been awarded a $1,065,568 Project Grant under the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420). The funding will support a 4-year research project to elucidate the mechanistic pathways of LMNA cardiomyopathy and evaluate novel therapeutic compounds. This award aims to advance medical solutions for the battlefield and transform healthcare for U.S. service members and the broader public...
The University of Texas MD Anderson Cancer Center will target glia-induced CDK5 expression that enforces antigenic escape of brain metastasis under a $729,000 project grant from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program administered by the Department of Defense to support innovative biomedical research that transforms military and public health care. Through basic, applied, and advanced research over three years from...